Helou Raphael, Rhalimi Mounir
Geriatric Department, Bertinot Juel Hospital, Chaumont en Vexin, France.
J Popul Ther Clin Pharmacol. 2010 Fall;17(3):e379-89. Epub 2010 Oct 26.
To evaluate whether Cholinesterase inhibitors (ChEI) are associated with an increased risk of pulmonary disorders (PD) in hospitalized dementia patients.
We conducted an observational cross-sectional study by examining the medical records of all the dementia patients hospitalized in the acute geriatric ward at the Bertinot Juel Hospital between January 1, 2005 and June 30, 2009. First, we examined whether there were any differences between the patients receiving ChEIs and those who were not. Second, we measured whether the patients had any type of PD outcome, including pneumonia, persistent cough, bronchitis, and asthma. Finally, we studied the association between ChEIs and PD. We used a logistic regression analysis preceded by a univariate analysis to adjust for other variables, such as age, weight, severity of dementia, length of stay in hospital, and history of asthma.
The study included 183 patients with a mean age of 83 years. There were 131 females and 52 males. There were 55 patients with PD, including 37 with pneumonia, 11 with bronchitis, 4 with asthma, 2 with acute respiratory failure and 1 with a persistent cough. In 38 of these cases, the PD was present before hospitalization and was considered the cause of hospitalization. In 17 cases, the PD was not present at admission but occurred during hospitalization. Only ChEI treatment and age (> 80 years) were associated with an increased risk of pulmonary disorders. The adjusted relative risk was 1.98 [1.21, 3.23] for ChEI and 1.30 [1.10, 1.54] for age.
When prescribing ChEIs, physicians should be aware about the risk of PD. As well, withdrawing ChEIs in patients who present repeated PD should be discussed. Prospective studies need to be conducted to confirm our findings.
评估胆碱酯酶抑制剂(ChEI)是否与住院痴呆患者肺部疾病(PD)风险增加相关。
我们通过检查2005年1月1日至2009年6月30日期间在贝尔蒂诺特·尤埃尔医院急性老年病房住院的所有痴呆患者的病历进行了一项观察性横断面研究。首先,我们检查接受ChEIs治疗的患者与未接受治疗的患者之间是否存在差异。其次,我们测量患者是否有任何类型的PD结局,包括肺炎、持续性咳嗽、支气管炎和哮喘。最后,我们研究ChEIs与PD之间的关联。我们在单变量分析之前使用逻辑回归分析来调整其他变量,如年龄、体重、痴呆严重程度、住院时间和哮喘病史。
该研究纳入了183例平均年龄为83岁的患者。其中女性131例,男性52例。有55例患者患有PD,包括37例肺炎、11例支气管炎、4例哮喘、2例急性呼吸衰竭和1例持续性咳嗽。在这些病例中,38例PD在住院前就已存在,并被认为是住院原因。17例患者入院时无PD,但在住院期间发生。只有ChEI治疗和年龄(>80岁)与肺部疾病风险增加相关。ChEI的调整后相对风险为1.98 [1.21, 3.23],年龄的调整后相对风险为1.30 [1.10, 1.54]。
在开具ChEIs处方时,医生应意识到PD的风险。此外,对于反复出现PD的患者,应讨论停用ChEIs。需要进行前瞻性研究以证实我们的发现。